Leqembi™ (lecanemab-irmb)

Leqembi (lecanemab‑irmb) is indicated for Alzheimer's disease but EviCore does not recommend approval/coverage due to insufficient evidence of clinically meaningful benefit and demonstrated safety concerns; treatment initiation is only supported for patients with mild cognitive impairment or mild dementia (the trial population) and initiation at earlier or later stages is not supported. This policy specifies no particular documentation, test results, or medical-record requirements.

"There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied."

Sign up to see full coverage criteria, indications, and limitations.